Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Clinical trial NCT04851119 · RECRUITING

Trial details

NCT number: NCT04851119
Sponsor: Children's Oncology Group
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Colorectal Carcinoma Endometrial Carcinoma Melanoma Neuroblastoma Ovarian Carcinoma Pancreatic Ductal Adenocarcinoma Recurrent Desmoid Fibromatosis Recurrent Ewing Sarcoma Recurrent Hepatoblastoma Recurrent Hepatocellular Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Non-Hodgkin Lymphoma

Start date: 2021-11-08
Primary completion: 2028-06-30
Enrollment: 147

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.